Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00337181 |
Recruitment Status
:
Active, not recruiting
First Posted
: June 15, 2006
Last Update Posted
: May 5, 2017
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
HIV-1 |
Study Type : | Observational |
Estimated Enrollment : | 130 participants |
Time Perspective: | Prospective |
Official Title: | Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Become HIV-1 Infected During Participation in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX® B/E. |
Study Start Date : | May 2006 |
Actual Primary Completion Date : | December 2006 |
Estimated Study Completion Date : | June 2017 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 31 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All individuals who become HIV-infected after receiving experimental vaccine or placebo in the RV144 clinical tria if they received at least injection.
- The volunteer must give written, informed consent.
Exclusion Criteria:
- Persons who have a medical or psychiatric disorder, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.
- Persons who become HIV-infected after the completion of the RV144 protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00337181
Thailand | |
Chon Buri Regional Hospital | |
Muang District, Chon Buri Province, Thailand, 20000 |
Principal Investigator: | Supachai Rerks-Ngarm, MD | Ministry of Health, Thailand |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | U.S. Army Medical Research and Materiel Command |
ClinicalTrials.gov Identifier: | NCT00337181 History of Changes |
Other Study ID Numbers: |
A-11048 RV152 CBER BB IND-8795 |
First Posted: | June 15, 2006 Key Record Dates |
Last Update Posted: | May 5, 2017 |
Last Verified: | May 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Keywords provided by U.S. Army Medical Research and Materiel Command:
HIV-1 Natural History HIV vaccine Thailand |
Additional relevant MeSH terms:
Vaccines Immunologic Factors Physiological Effects of Drugs |